Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation.
Yun Sok LeeMatthew RiopelPedro J CabralesGuatam K BandyopadhyayPublished in: Science advances (2019)
The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly by soluble factors released from obese adipocytes, leading to decreased incretin effects. Deletion of hepatocyte HIF-1α protected obesity-induced glucose intolerance without changes in body weight, liver steatosis, or insulin resistance. In-depth mouse metabolic phenotyping revealed that obesity increased first-pass degradation of an incretin hormone GLP-1 with increased liver DPP4 expression and decreased sinusoidal blood flow rate, reducing active GLP-1 levels in peripheral circulation. Hepatocyte HIF-1α KO blocked these changes induced by obesity. Deletion of hepatocyte HIF-2α did not change liver DPP4 expression but improved hepatic steatosis. Our results identify a previously unknown pathway for obesity-induced impaired beta cell glucose response (incretin effects) and the development of glucose intolerance through inter-organ communications.
Keyphrases
- insulin resistance
- weight loss
- metabolic syndrome
- high fat diet induced
- type diabetes
- weight gain
- poor prognosis
- adipose tissue
- high glucose
- endothelial cells
- liver injury
- drug induced
- blood flow
- bariatric surgery
- body weight
- diabetic rats
- blood glucose
- high fat diet
- stem cells
- body mass index
- high throughput
- cell therapy
- mesenchymal stem cells
- blood pressure
- atrial fibrillation